Associate Professor Zhang and his research team have developed a patented microfluidic system and process for the formulation of nanomedicines. The invention consists of a high-throughput microfluidic system, featuring a cartridge with a uniquely designed mixing channel, coupled with a desktop machine for conducting nanoparticle synthesis.
This system is designed to accelerate formulation screening and to enhance formulation optimisation, crucial for the development of gene therapy, cell therapy, and vaccines.
Associate Professor Nan Zhang, said, “The Covid-19 pandemic has led to an unprecedented loss of lives, and the development of mRNA vaccines has underscored the critical importance of nanomedicine in today's world. I sincerely hope that our high-throughput microfluidic formulation solution will significantly accelerate the development of nanomedicines.
Our aim is to enable patients suffering from cancer, infectious diseases, and rare conditions to have access to more effective and targeted treatments and to access the medicine as fast as possible, ultimately saving lives.”
Associate Professor Zhang is currently a participant in the 2024 UCD VentureLaunch Accelerator Programme at NovaUCD to support him and his new venture team to develop a viable business plan to commercialise this intellectual property.
He added, “We have established a commercialisation team focused on bringing the technology into a stage ready for external investment with the support of the NovaUCD team. Our plan is to launch a first laboratory-oriented system by mid-2025.”
Find out more via: https://lnkd.in/ejnNnKas
